Biofrontera

Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leverkusen, Germany, April  17, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2020.

Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020

Leverkusen, Germany, April  16, 2020  (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company has decided to propose to the Annual General Meeting a resolution for an ordinary capital increase. This proposed resolution includes but is not limited to the following contents:

Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting

Leverkusen, Germany, March  23, 2020  (GLOBE NEWSWIRE) -- On February 26, 2020, the Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds 2020/2024 (ISIN: DE000A254RS9) ("Bonds 2020/2024") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000 as well as up to 1,600,000 of the 1.00 % qualified subordinated mandatory convertible bonds 2020/2026 (ISIN: DE000A254RR1) ("Bonds 2020/2026") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000.

Biofrontera AG withdraws subscription offers for mandatory convertible bonds

Leverkusen, Germany, March  20, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that it has adopted comprehensive measures to reduce costs during the global COVID-19 pandemic.

Biofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic

Leverkusen, Germany, March  13, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with medac GmbH Sp. z o.o., the Polish branch of medac Gesellschaft für klinische Spezialpräparate mbH, for the marketing of Ameluz® and BF-RhodoLED® in Poland.

Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.

Leverkusen, Germany, March  12, 2020  (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds 2020/2024 (ISIN: DE000A254RS9) ("Bonds 2020/2024") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000. On February 26, 2020, the Management Board also resolved to issue up to 1,600,000 of the 1.00 % qualified subordinated mandatory convertible bonds 2020/2026 (ISIN: DE000A254RR1) ("Bonds 2020/2026") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000.

Biofrontera AG extends subscription period for mandatory convertible bonds

Leverkusen, Germany, March  10, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the European Commission has approved the use of Biofrontera’s prescription drug Ameluz® in combination with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) on the extremities and trunk/neck. In addition, the results of the follow-up phase of the clinical study comparing daylight PDT with Ameluz® and Metvix® were included in the product information (SmPC). With a recurrence rate of 19.5%, Ameluz® showed lower recurrence rates after 12 months than Metvix with 31.2%.

European Commission approves use of Ameluz® for the treatment of actinic keratosis on extremities and trunk/neck

Leverkusen, Germany, March  03, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered into a Binding Term Sheet with Maruho Co, Ltd, Osaka, Japan ("Maruho"), which sets out the main terms of a future license agreement. According to the Binding Term Sheet, the license agreement has the following main terms and conditions:

Biofrontera entered into binding term sheet with Maruho Co., Ltd.

Leverkusen, Germany, Feb.  19, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments.

Biofrontera provides clinical development updates

Leverkusen, Germany, Feb.  03, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion with respect to Biofrontera’s submission for label extension for its topical prescription drug Ameluz®. The extended approval will include photodynamic therapy (PDT) of mild and moderate actinic keratoses (AK) on the extremities and trunk/neck.

European Medicines Agency recommends indication expansion of Ameluz® for treatment of actinic keratoses on the extremities and trunk/neck

Leverkusen, Germany, Jan.  31, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that it has reorganized its European sales structure. The operational change was preceded by the reorganization of the Company’s US-subsidiary Biofrontera Inc. (published on 5 January 2020). As part of the restructuring of Biofrontera, Christoph Dünwald, Chief Commercial Officer (CCO), has resigned from his position to pursue new challenges.

Organizational restructuring of Biofrontera and resignation of Chief Commercial Officer Christoph Dünwald

Leverkusen, Germany, Jan.  14, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced follow-up results for its Phase III clinical study evaluating the safety and efficacy of photodynamic therapy (PDT) with Ameluz® and the BF-RhodoLED® lamp for the treatment of actinic keratosis (AK) on the extremities, trunk and neck. After 12 months, the overall lesion recurrence rates were 14.1% after Ameluz® treatment, compared to 27.4% after placebo treatment in the Full Analysis Set (FAS; 11.7% vs. 24.6% in the Per Protocol Set, respectively).

Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

Leverkusen, Germany, Jan.  10, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its results for the first nine months ended September 30, 2019. At the same time, the guidance for fiscal 2019 has been adjusted.

Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

Leverkusen, Germany, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new organizational structure of its American subsidiary Biofrontera Inc. to strengthen its commercial activities in the USA.

Biofrontera strengthens commercial focus with reorganization of its US business

Leverkusen, Germany, Dec.  20, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the results of the Extraordinary General Meeting held on December 19, 2019. The shareholders present represented 63.71% of the registered share capital.

Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority

Leverkusen, Germany, Dec.  13, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that Christopher Pearson has accepted the appointment as Chief Commercial Officer of Biofrontera Inc. in Woburn, MA effective January 06, 2020. He will be responsible for the divisions Sales & Marketing and Market Access at Biofrontera's US subsidiary.

Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.

Leverkusen, Germany, Nov.  22, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its participation at the following events:

Biofrontera to Participate in Upcoming Investor Conferences

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2019 Results - Earnings Call Transcript

Leverkusen, Germany, Nov.  19, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its results for the first nine months ended September 30, 2019. At the same time, the guidance for fiscal 2019 has been adjusted.

Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance

Leverkusen, Germany, Oct.  23, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with the "Poster of the Day" award at the renowned Fall Clinical Dermatology Conference in Las Vegas from October 17 to 20, 2019 for its latest Phase III clinical trial.

Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

Leverkusen, Germany, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2019.

Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

Leverkusen, Germany, Sept.  17, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof. Dr. Hermann Lübbert, Biofrontera’s CEO, will be presenting at the Baader Investment Conference. The conference will take place from September 23-27, 2019 at the Sofitel Munich Bayerpost in Munich, Germany. 

Biofrontera to present at the Baader Investment Conference

Leverkusen, Germany, Sept.  17, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label extension for Ameluz® with the European Medicines Agency (EMA) on August 28, 2019 to include treatment of mild and moderate actinic keratosis (AK) of the extremities and trunk/neck with photodynamic therapy (PDT). The submission follows the positive treatment outcomes demonstrated for Ameluz® in the recent phase III trial. 

Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck

Leverkusen, Germany, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating in the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference, held on September 12, 2019 at the Parker New York in New York City.

Biofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference

Biofrontera is cementing a place in the photodynamic therapy market.

News for Biofrontera Stock (BFRA)